Modern cold calling for Series A companies: the 90-day install for healthcare and life sciences in emerging markets
The exact 90-day plan for standing up modern cold calling at Series A — the point where the founder can no longer be every function. Written for commercial leaders at healthtech, medtech, and life-sciences companies in emerging markets.
This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in emerging markets. In this market, emerging-market buyers reward patient capital, currency-aware pricing, and a real local operating footprint, so the way you install modern cold calling has to be shaped to that reality from day one.
Series A is the moment modern cold calling stops being optional. The founder has to step out of some of the work, the plan requires a defensible growth number, and every quarter compounds toward the next raise.
Day 1 to 30: diagnosis and instrumentation. Name the constraint, write the ICP, wire connects per hour on ICP dials into the board pack.
Day 31 to 60: first live cycle at 20% of planned volume. Founder still in every review. Kill criteria written and enforced.
Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in emerging markets it is compounded by the fact that operating footprint and pricing fit, not brand awareness is what actually gates growth. Modern cold calling is only useful here when it is pointed at both constraints at once.
Day 61 to 90: ramp to full volume, hire the first dedicated operator, and hand off ops. Founder retains strategy and the weekly review.
By day 90 the metric is legible and the trajectory is defensible. This is what turns a Series A story into a Series B round.
Trap most Series A companies fall into: power dialers that torch the list in a week. It usually shows up around day 45 when the founder tries to hire ahead of the model.
The Series A version of modern cold calling looks small compared to what you will build at Series B. That is the point — it is a foundation, not a monument.
Concretely for healthcare and life sciences in emerging markets: the healthcare teams that install this get past procurement instead of dying in it, and the teams that install this early own the category before Western vendors even show up. That is the reason it is worth installing modern cold calling deliberately for this market rather than importing a playbook designed for somewhere else.
Frequently asked questions
Sales · healthcare · emerging markets — answered
- Does modern cold calling work for healthcare and life sciences in emerging markets?
- Yes — provided it is pointed at regulated-sale cycle length, not intent and adapted to the fact that in emerging markets, emerging-market buyers reward patient capital, currency-aware pricing, and a real local operating footprint. The healthcare teams that install this get past procurement instead of dying in it.
- Should we start modern cold calling before Series A?
- Yes if the founder has time; the Series A version is the same model at higher spend.
- How much of the round should fund modern cold calling?
- Meaningful — often 20–30% of the growth line — but only after diagnosis.
- When do we hire the first modern cold calling operator?
- Around day 60, once the model has run one full cycle with the founder.
- What Series A trap should we avoid?
- Power dialers that torch the list in a week — usually a premature senior hire.
- What is the emerging markets-specific pitfall when running modern cold calling for healthcare?
- Importing a playbook that was built for another market. In emerging markets, emerging-market buyers reward patient capital, currency-aware pricing, and a real local operating footprint — the install has to reflect that.
Growth Broker editorial
Filed under sales · healthcare · emerging markets